These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20687982)

  • 1. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids.
    Weinstein SF; Corren J; Murphy K; Nolte H; White M;
    Allergy Asthma Proc; 2010; 31(4):280-9. PubMed ID: 20687982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids.
    Nathan RA; Nolte H; Pearlman DS;
    Allergy Asthma Proc; 2010; 31(4):269-79. PubMed ID: 20678306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function.
    Meltzer EO; Kuna P; Nolte H; Nayak AS; Laforce C;
    Eur Respir J; 2012 Feb; 39(2):279-89. PubMed ID: 21828036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma.
    Maspero JF; Nolte H; Chérrez-Ojeda I;
    J Asthma; 2010 Dec; 47(10):1106-15. PubMed ID: 20874458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Gates D; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():73-86. PubMed ID: 22334770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent anti-inflammatory effect of inhaled mometasone furoate/formoterol in subjects with asthma.
    Nolte H; Pavord I; Backer V; Spector S; Shekar T; Gates D; Nair P; Hargreave F
    Respir Med; 2013 May; 107(5):656-64. PubMed ID: 23490226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial.
    Tashkin DP; Doherty DE; Kerwin E; Matiz-Bueno CE; Knorr B; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():43-55. PubMed ID: 22334768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.
    Doherty DE; Tashkin DP; Kerwin E; Knorr BA; Shekar T; Banerjee S; Staudinger H
    Int J Chron Obstruct Pulmon Dis; 2012; 7():57-71. PubMed ID: 22334769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 3 study evaluating the safety and efficacy of a pediatric dose of mometasone furoate with and without formoterol for persistent asthma.
    Weinstein CLJ; Gates D; Zhang X; Varnell T; Mok W; Vermeulen JH; Amar NJ; Jain N
    Pediatr Pulmonol; 2020 Apr; 55(4):882-889. PubMed ID: 32022483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler.
    Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD
    Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mometasone furoate/formoterol in the treatment of persistent asthma.
    Berger WE
    Expert Rev Respir Med; 2011 Dec; 5(6):739-46. PubMed ID: 22082160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the systemic bioavailability of mometasone furoate after oral inhalation from a mometasone furoate/formoterol fumarate metered-dose inhaler versus a mometasone furoate dry-powder inhaler in patients with chronic obstructive pulmonary disease.
    Kosoglou T; Hubbell J; Xuan F; Cutler DL; Meehan AG; Kantesaria B; Wittmer BA
    Int J Chron Obstruct Pulmon Dis; 2013; 8():107-16. PubMed ID: 23525511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma.
    Berger WE; Bensch GW; Weinstein SF; Skoner DP; Prenner BM; Shekar T; Nolte H; Teper AA
    Pediatr Pulmonol; 2014 May; 49(5):441-50. PubMed ID: 24019197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
    Karpel JP; Busse WW; Noonan MJ; Monahan ME; Lutsky B; Staudinger H
    Ann Pharmacother; 2005 Dec; 39(12):1977-83. PubMed ID: 16264062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma.
    FitzGerald JM; Boulet LP; Follows RM
    Clin Ther; 2005 Apr; 27(4):393-406. PubMed ID: 15922813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
    Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
    Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
    Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.
    Scicchitano R; Aalbers R; Ukena D; Manjra A; Fouquert L; Centanni S; Boulet LP; Naya IP; Hultquist C
    Curr Med Res Opin; 2004 Sep; 20(9):1403-18. PubMed ID: 15383189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.